EE327 Belantamab Mafodotin, Pomalidomide, and Dexamethasone (BPd) in Relapsed/Refractory Multiple Myeloma (RRMM): Quality-Adjusted Life-Year (QALY) Results From a Cost-Effectiveness Model
Abstract
Authors
Attaya Suvannasankha Martin Kaiser Dawn Lee Ewa Dlotko Paul Macleod Natalie Boytsov Christina-Jane Crossman-Morgan Vinay Jadhav Gbenga Kazeem Adil Merchant Molly Purser Justin Riemer Yevgeniy SAMYSHKIN Simon McNamara